How CDMOs are reshaping pharmaceutical partnerships through friendshoring, risk-sharing economics, and specialized development capabilities.
The pharmaceutical manufacturing landscape is undergoing a profound shift, with...more
Recently, the Delaware Chancery Court and the Third Circuit issued three significant decisions on key issues affecting licensing and M&A transactions in the life sciences industry....more
9/16/2024
/ Acquisitions ,
Breach of Contract ,
Commercially Reasonable Efforts ,
Due Diligence ,
Earn-Outs ,
IP License ,
Johnson & Johnson ,
Life Sciences ,
Medical Devices ,
Mergers ,
Patents ,
Pharmaceutical Industry ,
Royalties ,
Shareholders